Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Experimental Cancer Drug Shrinks Tumors and Extends Survival in Metastatic Colorectal Cancer Patients

02.06.2003


An experimental cancer drug named bevacizumab (trade name Avastin) is the first "anti-angiogenesis" drug to prove that it can shrink tumors and extend survival in patients with metastatic colorectal cancer, according to a national clinical trial led by researchers at the Duke Comprehensive Cancer Center.



Bevacizumab is known as an anti-angiogenesis drug because it blocks the formation of blood vessels in tumors (a process called angiogenesis) and thus inhibits their growth.

Patients who received bevacizumab together with standard chemotherapy survived a median of five months longer than patients who received standard chemotherapy alone, the study showed. A five-month life extension is quite significant, given that patients with newly diagnosed colorectal cancer survive an average of 15 to 17 months, said Herbert Hurwitz, M.D., lead investigator of the study and an assistant professor of medicine at Duke University Medical Center.


Furthermore, the new study lends critical support to the long-debated approach of choking off a tumor’s blood supply in order to inhibit tumor growth, said Hurwitz. This anti-angiogenesis approach has been touted as a plausible strategy against tumors but has never been proven successful in a large, randomized group of patients -- until now.

Hurwitz presented the results of the study, funded by Genentech, Inc., today (June 1) at the annual meeting of the American Society of Clinical Oncology in Chicago.

"Our study offers important proof of the philosophy that targeting a tumor’s blood supply can, in fact, inhibit the tumor’s ability to proliferate," said Hurwitz. "Moreover, our current success will likely lead the cancer community to conduct large-scale clinical testing of bevacizumab as a treatment for other types of cancers."

In the current study, approximately 800 patients at various institutions nationwide were randomly assigned to receive bevacizumab plus standard chemotherapy (irinotecan, 5-FU, and leucovorin), or the standard chemotherapy with placebo.

Patients who received bevacizumab plus chemotherapy survived a median of 20.3 months, compared to 15.6 months for patients who received standard chemotherapy alone. Bevacizumab also delayed cancer progression for a median of 10.6 months versus 6.2 months for the standard chemotherapy. In addition, the bevacizumab and chemotherapy combination shrank tumors by at least half in 45 percent of patients, versus 35 percent in patients receiving standard chemotherapy alone.

"Metastatic colorectal cancer is a very aggressive disease, so we view these results with real optimism, as we now have another weapon in the fight against this cancer," said Hurwitz.

Bevacizumab works by inhibiting a protein called vascular endothelial growth factor (VEGF), which is secreted by malignant tumors in order to grow and maintain their blood vessels. When VEGF is blocked by bevacizumab, the tumor’s blood is diminished and the tumor shrinks and slows its spread.

Bevacizumab has fewer side effects than standard chemotherapy because it selectively targets blood vessels within tumors, which secrete more VEGF than do normal blood vessels in the body. The most frequent side effect was a moderate elevation in blood pressure, which was easily managed by medications, the study showed.

Hurwitz said that, while the bevacizumab results are very encouraging, the drug represents one of many weapons in a battery of drugs designed to combat the disease.

"Cancer is a very savvy opponent, and it often devises ways to circumvent our current methods of inhibiting it," said Hurwitz. "In addition, each tumor has its own characteristics that may cause it to behave differently from another patient’s tumor. For these reasons, no single therapy will work for every patient, so it’s important to develop multiple ways of combating the growth and spread of cancer."

Becky Levine | DukeNews
Further information:
http://dukemednews.org/news/article.php?id=6612

More articles from Health and Medicine:

nachricht How cancer metastasis happens: Researchers reveal a key mechanism
19.01.2018 | Weill Cornell Medicine

nachricht Researchers identify new way to unmask melanoma cells to the immune system
17.01.2018 | Duke University Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

Im Focus: Room-temperature multiferroic thin films and their properties

Scientists at Tokyo Institute of Technology (Tokyo Tech) and Tohoku University have developed high-quality GFO epitaxial films and systematically investigated their ferroelectric and ferromagnetic properties. They also demonstrated the room-temperature magnetocapacitance effects of these GFO thin films.

Multiferroic materials show magnetically driven ferroelectricity. They are attracting increasing attention because of their fascinating properties such as...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Let the good tubes roll

19.01.2018 | Materials Sciences

How cancer metastasis happens: Researchers reveal a key mechanism

19.01.2018 | Health and Medicine

Meteoritic stardust unlocks timing of supernova dust formation

19.01.2018 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>